ADVERTISEMENT

Covaxin Gets CDSCO Approval for Vaccine Shelf Life Extension to 12 Months

CDSCO has approved the extension of shelf life of indigenously-developed Covaxin from nine to twelve months.

Published
Breaking News
1 min read
Covaxin Gets CDSCO Approval for Vaccine Shelf Life Extension to 12 Months
i

India's drug regulator, the Central Drugs Standards Control Organisation (CDSCO) has approved the extension of shelf life of indigenously-developed COVID-19 vaccine Covaxin from nine to twelve months.

The Hyderabad-based Bharat Biotech on Wednesday, 3 November announced that the CDSCO approved the extension of shelf life of the vaccine up to 12 months, from the date of manufacture.

"This approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO. The shelf life extension has been communicated to our stakeholders," the vaccine maker said.

ADVERTISEMENT
It was initially given permission for sale and distribution of Covaxin with a shelf life of six months when stored at two to eight degrees Celsius.

The CDSCO later gave its approval for extending the shelf life to nine months after Bharat Biotech submitted updated accelerated and real-time stability data of Covaxin.

Covaxin, along with Covishield manufactured by Serum Institute of India, are the two vaccines so far being used in India's current COVID-19 vaccination drive, which was launched in January this year.

Russian vaccine Sputnik-V has also been approved for emergency use in India.

(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)

Read and Breaking News at the Quint, browse for more from news and breaking-news

Topics:  Bharat Biotech   covaxin   covid vaccine 

ADVERTISEMENT
Speaking truth to power requires allies like you.
Become a Quint Insider
25
100
200

or more

PREMIUM

3 months
12 months
12 months
Check Insider Benefits
Read More
ADVERTISEMENT
Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!
ADVERTISEMENT
More News
×
×